# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Diagnostics Assessment Programme <br> Transperineal biopsy in people with suspected prostate cancer <br> Stakeholder list 

## Manufacturers

BK Medical UK Ltd
BXTAccelyon Limited
Delta Surgical Ltd
Hitachi Medical Systems UK Ltd
JEB Technologies Ltd
Kebomed UK
Manufacturers of related technologies (not included in scope)
BD
Focal Healthcare
Medical Targeting Technologies GmbH
MedCom GmbH
Mermaid Medical Ltd
Philips Electronics UK Limited

## Patient/carer groups

Prostate Cancer UK

## Professional groups

British Association of Urological Surgeons
Royal College of Physicians
The Royal College of Pathologists
Provider of NHS Services in England
Cambridge University Hospitals NHS trust
Royal Surrey Foundation Trust Hospital

## Research organisations

Nuffield Department of Surgical Sciences, University of Oxford

## External Assessment Group

Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, UK

## Others

Academic Health Science Network
Department of Health
Healthcare Improvement Scotland
Medicines and Healthcare products Regulatory Agency
NHS England
The Urology Foundation
Welsh Government
Specialist committee member applicants

## Definitions:

## Stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

## External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technologies.

